{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:05:44Z","timestamp":1769573144889,"version":"3.49.0"},"reference-count":34,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852921000572_sec1\"><jats:title>Background<\/jats:title><jats:p>The aim of this study is to examine the effects of quetiapine as an adjuvant treatment for obsessive\u2013compulsive (OC) symptoms in patients with bipolar disorder (BD) type I.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000572_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>In this 8-week double-blind placebo-controlled randomized clinical trial, 47 patients with BD in euthymic phase that had OC symptoms were randomly allocated to receive either quetiapine or placebo plus their routine medications (lithium\u00a0+\u00a0clonazepam). Yale\u2013Brown Obsessive\u2013Compulsive Scale (YBOCS) was used to assess the outcomes. Adverse effects were also recorded.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000572_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Of 47 BD patients with OC symptoms that were randomly allocated in two groups of quetiapine (n\u00a0=\u00a024) and placebo group (n\u00a0=\u00a023), 40 patients (20 in quetiapine group and 20 in placebo group) completed the trial. Throughout the trial, the mean score of YBOCS in the quetiapine group dropped from 24.37\u00a0\u00b1\u00a01.51 to 15.26\u00a0\u00b1\u00a01.16 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) and in the placebo group decreased from 24.21\u00a0\u00b1\u00a01.33 to 23.94\u00a0\u00b1\u00a01.66 (<jats:italic>P<\/jats:italic>\u00a0=\u00a01.97). At the end of the study, 12 (60%) patients in the quetiapine group and 1 (5%) patient in the placebo group had more than 34% decline in YBOCS score (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). No serious adverse effects were reported in two groups.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000572_sec4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Our double-blind placebo-controlled clinical trial showed that quetiapine may be an effective adjuvant agent for reducing OC symptoms in BD patients.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852921000572","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T10:17:20Z","timestamp":1621851440000},"page":"634-638","source":"Crossref","is-referenced-by-count":5,"title":["Is quetiapine effective for obsessive and compulsive symptoms in patients with bipolar disorder? A randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1017","volume":"27","author":[{"given":"Ali","family":"Sahraian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahareh","family":"Ghahremanpouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2283-2751","authenticated-orcid":false,"given":"Arash","family":"Mowla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"S1092852921000572_r7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0316"},{"key":"S1092852921000572_r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.06.015"},{"key":"S1092852921000572_r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2009.07.006"},{"key":"S1092852921000572_r18","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.2.219"},{"key":"S1092852921000572_r28","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852919001500"},{"key":"S1092852921000572_r4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.5.543"},{"key":"S1092852921000572_r20","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318185e735"},{"key":"S1092852921000572_r34","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000651"},{"key":"S1092852921000572_r17","article-title":"Quetiapine for schizophrenia","volume":"2004","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852921000572_r29","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852912000065"},{"key":"S1092852921000572_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.12.019"},{"key":"S1092852921000572_r1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12593"},{"key":"S1092852921000572_r2","doi-asserted-by":"publisher","DOI":"10.1159\/000449417"},{"key":"S1092852921000572_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.05.015"},{"key":"S1092852921000572_r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2009.11.001"},{"key":"S1092852921000572_r25","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-020-09753-2"},{"key":"S1092852921000572_r19","first-page":"5","article-title":"Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing","volume":"63","author":"Nemeroff","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"S1092852921000572_r3","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(95)02752-1"},{"key":"S1092852921000572_r16","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.150136"},{"key":"S1092852921000572_r26","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"S1092852921000572_r31","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"S1092852921000572_r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.02.024"},{"key":"S1092852921000572_r6","doi-asserted-by":"publisher","DOI":"10.1159\/000077740"},{"key":"S1092852921000572_r23","article-title":"Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials","author":"Kishi","year":"2020","journal-title":"Mol Psychiatry"},{"key":"S1092852921000572_r11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.3.182"},{"key":"S1092852921000572_r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.03.014"},{"key":"S1092852921000572_r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2004.08.004"},{"key":"S1092852921000572_r21","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182367aee"},{"key":"S1092852921000572_r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2014.05.006"},{"key":"S1092852921000572_r30","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S1092852921000572_r14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2008.00637.x"},{"key":"S1092852921000572_r24","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000325"},{"key":"S1092852921000572_r22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04269"},{"key":"S1092852921000572_r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.08.012"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852921000572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T10:26:04Z","timestamp":1666693564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852921000572\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1092852921000572"],"URL":"https:\/\/doi.org\/10.1017\/s1092852921000572","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]}}}